scholarly journals Clinical Practice Guidelines of Traditional Chinese Herbal Medicine for Novel Coronavirus (Covid-19): Protocol of a Systematic Review

2020 ◽  
Author(s):  
Yuxi Li ◽  
Juan Li ◽  
Dongling Zhong ◽  
Yue Zhang ◽  
Yonggang Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Practice ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Practice Guidelines ◽  
Agree Ii ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Novel Coronavirus

Abstract Background: The World Health Organization declared on 11 March 2020 that thespread of the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) had escalated from epidemic into pandemic. As the initial outbreak area, China has taken multiple active measures to deal with the epidemic. Updated versions of diagnosis and treatment guideline for novel coronavirus (COVID-19)patients have been issued, and traditional Chinese herbal medicine has been recommended as a treatment.Methods: In this systematic review, we will search for guidelines, expert consensuses and policy documents published since December 2019 in electronic databases and on websites of governments or organizations. Eligible documents will be independently selected, and relevant data will be independently extracted by two reviewers. We will also independently evaluate the methodological quality and reporting quality of the included guidelines, using the Appraisal of Guidelines for REsearch& Evaluation (AGREE) II tool and Reporting Items for Practice Guidelines in healthcare (RIGHT) statement, respectively. Any discrepancies will be discussed and resolved through discussion among the reviewers. We will use the extracted information to summarize their recommendationsfor traditional Chinese herbal formulae and Chinese patent medicine for COVID-19 patients, and to summarize the strength and quality of these recommendations with reference to the findings from the AGREE II and RIGHT tools.Discussion: This review will summarize the recommendations in current clinical practice guidelines andprovide insight into the implementation strategies for traditional Chinese herbal medicine in COVID-19 patients. Systematic review registration: PROSPERO registration number: CRD42020179205

scholarly journals Clinical practice guidelines and experts’ consensuses of traditional Chinese herbal medicine for novel coronavirus (COVID-19): protocol of a systematic review

2020 ◽  
Author(s):  
Yuxi Li ◽  
Juan Li ◽  
Dongling Zhong ◽  
Yue Zhang ◽  
Yonggang Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Practice ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Reporting Quality ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal

Abstract Background: The World Health Organization declared on 11 March 2020 that the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has escalated from epidemic into pandemic. As the initial outbreak area, China has taken multiple active measures to deal with the epidemic. Updated versions of diagnosis and treatment guideline for novel coronavirus (COVID-19) patients have been issued, and traditional Chinese herbal medicine has been recommended as a treatment. The objective of this study will be to summarize the recommendations in current clinical practice guidelines about the use of traditional Chinese herbal medicine for COVID-19 patients. We will also evaluate and report on the methodological and reporting quality of these guidelines.Methods: In this systematic review, we will search for guidelines, expert consensuses and policy documents published since December 2019 in electronic databases (e.g. PubMed, EMBASE, and Chinese databases) and on websites of governments or organizations (e.g. The National Guideline Clearinghouse [NGC], Guidelines International Network [GIN], National Institute for Health and Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network [SIGN] and WHO]). Eligible documents will be independently selected, and relevant data will be independently extracted by two reviewers. We will also independently evaluate the methodological quality and reporting quality of the included guidelines, using the Appraisal of Guidelines for REsearch & Evaluation (AGREE) II tool and Reporting Items for Practice Guidelines in healthcare (RIGHT) statement, respectively. Any discrepancies will be discussed and resolved through discussion among the reviewers. We will use the extracted information to summarize their recommendations for traditional Chinese herbal formulae and Chinese patent medicine for COVID-19 patients, and to summarize the strength and quality of these recommendations with reference to the results of AGREE II and RIGHT tools.Discussion: This review will summarize the recommendations in current clinical practice guidelines and provide insight into the implementation strategies for traditional Chinese herbal medicine in COVID-19 patients. Systematic review registration: PROSPERO registration number: CRD42020179205

scholarly journals Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis

2020 ◽  
Author(s):  
Yuxi Li ◽  
Xiaobo Liu ◽  
Liuxue Guo ◽  
Juan Li ◽  
Dongling Zhong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Meta Analysis ◽  
Biomedical Literature ◽  
World Health ◽  
Cochrane Central Register ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Novel Coronavirus

Abstract Background A new type of coronavirus, novel coronavirus (COVID-19), is causing an increasing number of cases of pneumonia and was declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China in late December 2019 and traditional Chinese herbal medicine is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of traditional Chinese herbal medicine in COVID-19 pneumonia. Methods We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP) and Wanfang database using keywords related to COVID-19 and traditional Chinese herbal medicine. Reference lists of relevant trials and reviews will be searched. We will manually search grey literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies (XL and DZ), extract data (YL and LG) and evaluate risk of bias (YL and DZ). Data analysis will be conducted using Review Manager software (version 5.3.5) and R software (version 3.6.1). Statistical heterogeneity will be assessed using a standard Chi-square test with a significance level of P < 0.10. Biases associated with study size (e.g. publication bias) will be investigated using funnel plots, the Egger 's test and Begg 's test and Trim and Fill analysis. Discussion This study will provide a high-quality synthesis of the effects of traditional Chinese herbal medicine for COVID-19. The use of traditional Chinese herbal medicine for treatment or prevention of these novel viral infections affecting the pneumonia will be investigated. Systematic review registration PROSPERO registration number: CRD42020168004

scholarly journals Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines

2019 ◽  
Vol 47 (3) ◽  
pp. 262-269 ◽  
Author(s):  
Pradeep M. Jayaram ◽  
Manoj K. Mohan ◽  
Ibrahim Farid ◽  
Stephen Lindow
Keyword(s):  
Systematic Review ◽  
Clinical Practice ◽  
Magnesium Sulfate ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Supporting Evidence ◽  
Agree Ii ◽  
Fetal Neuroprotection ◽  
Agree Ii Tool

Abstract Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There are some perceived differences in the international recommendations on the use magnesium sulfate for fetal neuroprotection in preterm labor. Content This systematic review analyses the available clinical guidelines for the use of magnesium sulfate for fetal neuroprotection and compares the recommendations, and assesses the quality of guidelines. This provides the consensus, differences and explores the areas for future collaborative research. We searched databases of PUBMED, EMBASE, COCHRANE, Web of Science, LILACS; and included the national and the international clinical practice guidelines. We included seven guidelines out of 227 search results. We evaluated the methodological quality of guidelines using the Appraisal of Guidelines Research and Evaluation (AGREE II) tool and systematically extracted guideline characters, recommendation and supporting evidence base. Summary Five guidelines were of high quality and two were of moderate quality. One guideline achieved more than an 80% score in all the domains of AGREE II tool. All guidelines recommend use of magnesium sulfate for fetal neuroprotection. However, there are differences in other recommendations such as upper gestational age, dose, duration, repeating treatment and use of additional tocolytics. Outlook Future guidelines should include recommendations on all aspects of magnesium sulfate therapy for fetal neuroprotection. Future research and international collaboration should focus on areas where there are no international consensual recommendations.

scholarly journals Overview of evidence-based clinical practice guidelines for preoperative care: a systematic review.

2020 ◽  
Author(s):  
Agustín Ciapponi ◽  
Tapia-López Elena ◽  
Virgilio Sacha ◽  
Ariel Bardach
Keyword(s):  
Systematic Review ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cochrane Library ◽  
Evidence Based ◽  
Agree Ii ◽  
Quality Of Evidence ◽  
Moderate Quality

Abstract Background Our aim was to summarize and compare relevant recommendations from evidence-based CPGs (EB-CPGs). Methods Systematic review of clinical practice guidelines. Data sources: PubMed, EMBase, Cochrane Library, LILACS, Tripdatabase and additional sources. In July 2017, we searched CPGs that were published in the last 10 years, without language restrictions, in electronic databases, and also searched specific CPG sources, reference lists and consulted experts. Pairs of independent reviewers selected EB-CPGs and rated their methodological quality using the AGREE-II instrument. We summarized recommendations, its supporting evidence and strength of recommendations according to the GRADE methodology. Results We included 16 EB-CPGs out of 2262 references identified. Only nine of them had searches within the last five years and seven used GRADE. The median (percentile 25-75) AGREE-II scores for rigor of development was 49% (35-76%) and the domain ‘applicability’ obtained the worst score: 16% (9-31%). We summarized 31 risk stratification recommendations, 21.6% of which were supported by high/moderate quality of evidence (41% of them were strong recommendations), and 16 therapeutic/preventive recommendations, 59% of which were supported by high/moderate quality of evidence (75.7% strong). We found inconsistency in ratings of evidence level. ‘Guidelines’ applicability’ and ‘monitoring’ were the most deficient domains. Only half of the EB-CPGs were updated in the past five years. Conclusions We present many strong recommendations that are ready to be considered for implementation as well as others to be interrupted, and we reveal opportunities to improve guidelines’ quality.

Sign in / Sign up

Export Citation Format

Share Document